HOME >> BIOLOGY >> NEWS
Small gene changes in some leukemia patients may explain varying responses to chemotherapy

A new study provides evidence that may explain why some patients with chronic lymphocytic leukemia (CLL) are resistant to chemotherapy and have a shorter survival time and may identify a potential new target for treating the disease. Patients who had an insertion in the promoter region of a gene that regulates apoptosis, or programmed cell death, were more likely to have a poor response to chemotherapy and to have a rapid progression of the disease, according to the study, which is published in the May 5 issue of the Journal of the National Cancer Institute.

CLL is the most common form of leukemia in the United States: about 12,000 new cases are diagnosed each year. Unlike most cancers that occur because cells divide uncontrollably, CLL is caused primarily by defective apoptosis. Cells live an unnaturally long time and fail to die when they should. Patients diagnosed with CLL can live for months or years and can have varying responses to chemotherapy, although researchers do not know why this is the case or how to predict a patient's prognosis.

Increased levels of a protein called Mcl-1 have previously been associated with a lack of response to chemotherapy in CLL patients. To explore the mechanisms that might be responsible for these increased levels, Anurag Saxena, M.D., of the University of Saskatchewan and the Royal University Hospital in Saskatoon, Saskatchewan, Canada, and colleagues sequenced the MCL-1 gene from 58 CLL patients and 18 control subjects. They also measured expression levels of MCL-1 mRNA and Mcl-1 protein.

The researchers found insertions of 6 or 18 nucleotides in the promoter region of the MCL-1 gene in 17 of 58 CLL patients and in none of the controls. The insertions were all found in the same site in the promoter, in a region that contains binding sites for several transcription factors. Transcription factors are proteins that initiate or regulate the transcription of DNA into mRNA. Patients with the insertion
'"/>

Contact: Sarah L. Zielinski
jncimedia@oupjournals.org
301-841-1287
Journal of the National Cancer Institute
4-May-2004


Page: 1 2

Related biology news :

1. Small, Smac-like molecule encourages death of cancer cells
2. Small animal imaging gives cancer clues
3. Small RNA surmounts large cancer problem
4. Small, cold, & hungry: Ultra-small microbes from 120,000-year-old glacier ice sample
5. Small trial shows daclizumab add-on therapy improves MS outcome
6. Small amounts of alcohol or anesthetics may damage the developing brain
7. Smallpox in 50-year-old tissues detected by integrated diagnostics approach
8. Small-molecule inhibitors of anthrax lethal factor identified
9. Smallpox in Europe selected for genetic mutation that confers resistance to HIV infection
10. Small-molecule inhibitors of botulinum neurotoxin identified
11. Smallest whirlpools can pack stunningly strong force

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:1/8/2019)... (PRWEB) , ... January 07, 2019 , ... ... and compliance solutions, is proud to welcome Thomas Kennedy as head of sales ... Miglicco, CEO for PureWay. , Mr. Kennedy has previously worked for Johnson & ...
(Date:1/7/2019)... ... January 07, 2019 , ... Franz Inc. , ... technology for Knowledge Graphs solutions, announced that it was recognized by Database ... DBTA’s data and information management recognition list includes newer approaches leveraging artificial intelligence, ...
(Date:1/4/2019)... (PRWEB) , ... January 03, 2019 , ... ... adopt 3D cell culture models into their drug discovery research workflows with biology ... improve the in vivo relevancy of in vitro studies, they create several challenges ...
Breaking Biology News(10 mins):
(Date:12/20/2018)... Colo. (PRWEB) , ... December 20, 2018 , ... New ... 2019, with major changes in regulations in the European Union (EU) on the horizon, ... companies to consider. , “The transition to the EU Medical Device Regulation (MDR), digital ...
(Date:12/19/2018)... ... December 19, 2018 , ... ... the validated release of Limfinity® version 7.1. The new release enhances the latest ... RURO as 2018 comes to an end. , Validation protocols, and their execution, ...
(Date:12/18/2018)... ... December 18, 2018 , ... USDM ... for the life sciences industry, unveiled a completely redesigned website at http://www.usdm.com ... user-friendly browsing experience for their valued clients and business partners. , The ...
(Date:12/14/2018)... ... December 14, 2018 , ... NOVA OCULUS PARTNERS, LLC, ... green light to immediately begin a clinical patient trial in Edmonton using their ... of Health Canada has granted what is called an Investigational Testing Authorization for ...
Breaking Biology Technology:
Cached News: